Latest Scilex Pharmaceuticals Inc. Stories
MALVERN, Pa., Sept.
MALVERN, Pa., Aug.
All studies on track for completion and final study reports by November 2014 MALVERN, Pa., Aug.
The Company expects the studies, along with the PK study, to be completed in the 4th quarter of 2014 MALVERN, Pa., July 14, 2014 /PRNewswire/ -- SCILEX Pharmaceuticals,
Scilex has commenced with its pivotal bioequivalence study of Ztilido versus Lidoderm® in accordance with FDA recommendations to support approval of Ztilido submitted as a 505(b)(2) NDA
Mr. Sendrow Joins Pharmaceuticals Product Development and Regulatory Expert Eric Floyd, Ph.D.
Pivotal pharmacokinetic bridging clinical study anticipated to begin in May MALVERN, Pa., March 24, 2014 /PRNewswire/ -- Scilex Pharmaceuticals, Inc., a company engaged in the development
Funds to be used for the clinical development of the Company's first product Ztilido(TM) (lidocaine patch 1.8%) MALVERN, Pa., March 21, 2014 /PRNewswire/ -- Scilex Pharmaceuticals,